Forums
New posts
Search forums
What's new
New posts
New media
New media comments
Latest activity
Classifieds
Media
New media
New comments
Search media
Log in
Register
What's New?
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More Options
Advertise with us
Contact Us
Close Menu
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Forums
The Water Cooler
General Discussion
Poll: Marijuana Law Reform
Search titles only
By:
Reply to Thread
This site may earn a commission from merchant affiliate links, including eBay, Amazon, and others.
Message
<blockquote data-quote="_CY_" data-source="post: 2758219" data-attributes="member: 7629"><p>NIH technical paper below is dated Feb 2008 .. yet the official line is still pot has NO medicinal properties and is still a class III narcotic</p><p></p><p>==============</p><p></p><p>TIL THC has 20 times anti-inflammatory power of aspirin, twice that of hydrocortisone (ncbi.nlm.nih.gov)</p><p><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/" target="_blank">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/</a></p><p></p><p><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/pdf/tcrm-0401-245.pdf" target="_blank">full text pdf </a></p><p></p><p>Cannabinoids in the management of difficult to treat pain</p><p></p><p>Abstract</p><p></p><p>This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment. Tetrahydrocannabinol (THC, Marinol®) and nabilone (Cesamet®) are currently approved in the United States and other countries, but not for pain indications. Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation. Sativex®, a cannabis derived oromucosal spray containing equal proportions of THC (partial CB1 receptor agonist ) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB1 receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006. Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.</p><p>Keywords: cannabinoids, tetrahydrocannabinol, cannabidiol, analgesia, pain management, multiple sclerosis</p></blockquote><p></p>
[QUOTE="_CY_, post: 2758219, member: 7629"] NIH technical paper below is dated Feb 2008 .. yet the official line is still pot has NO medicinal properties and is still a class III narcotic ============== TIL THC has 20 times anti-inflammatory power of aspirin, twice that of hydrocortisone (ncbi.nlm.nih.gov) [url]http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/[/url] [URL="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/pdf/tcrm-0401-245.pdf"]full text pdf [/URL] Cannabinoids in the management of difficult to treat pain Abstract This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment. Tetrahydrocannabinol (THC, Marinol®) and nabilone (Cesamet®) are currently approved in the United States and other countries, but not for pain indications. Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation. Sativex®, a cannabis derived oromucosal spray containing equal proportions of THC (partial CB1 receptor agonist ) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB1 receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006. Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise. Keywords: cannabinoids, tetrahydrocannabinol, cannabidiol, analgesia, pain management, multiple sclerosis [/QUOTE]
Insert Quotes…
Verification
Post Reply
Forums
The Water Cooler
General Discussion
Poll: Marijuana Law Reform
Search titles only
By:
Top
Bottom
